

Supplementary table 1. Association between antibodies and manifestations in JSLE

		Mucocutaneous			LN			NPSLE			Serositis			Arthritis		
		Involved	Not involved	² χ	Involved	Not involved	² χ	Involved	Not involved	² χ	Involved	Not involved	² χ	Involved	Not involved	² χ
Anti-Ro52/SSA	Positive n(%)	27 87.1%	4 12.9%	0.003 <i>P</i> =0.957	11 35.5%	20 64.5%	1.343 <i>P</i> =0.247	7 22.6%	24 77.4%	1.032 <i>P</i> =0.310	9 29%	22 71%	0.454 <i>P</i> =0.500	10 32.3%	21 67.7%	0.279 <i>P</i> =0.597
	Negative n(%)	39 86.7%	6 13.3%		22 48.9%	23 51.5%		15 33.3%	30 66.7%		10 19%	35 57%		12 26.7%	33 73.3%	
Anti-Ro60/SSA	Positive n(%)	34 94.4%	2 5.6%	2.311 <i>P</i> =0.128	15 41.7%	21 58.3%	0.086 <i>P</i> =0.770	8 22.2%	28 77.8%	1.504 <i>P</i> =0.220	11 30.6%	25 69.4%	1.126 <i>P</i> =0.289	10 27.8%	26 72.2%	0.045 <i>P</i> =0.831
	Negative n(%)	32 80%	8 20%		18 45%	22 55%		14 35%	26 65%		8 19%	32 57%		12 30%	28 70%	
Anti-La/SSB	Positive n(%)	8 72.7%	3 27.3%	2.242 <i>P</i> =0.134	5 45.5%	6 54.5%	0.022 <i>P</i> =0.883	2 18.2%	9 81.8%	0.242 <i>P</i> =0.623	5 45.5%	6 54.5%	1.736 <i>P</i> =0.188	4 36.4%	7 63.6%	0.052 <i>P</i> =0.820
	Negative n(%)	58 89.2%	7 10.8%		28 43.1%	37 56.9%		20 30.8%	45 69.2%		14 21.5%	51 78.5%		18 27.7%	47 72.3%	
Anti-Sm	Positive n(%)	21 95.5%	1 4.5%	1.089 <i>P</i> =0.297	10 45.5%	12 54.5%	0.052 <i>P</i> =0.819	5 22.7%	17 77.3%	0.582 <i>P</i> =0.445	4 18.2%	18 81.8%	0.768 <i>P</i> =0.381	7 31.8%	15 68.2%	0.124 <i>P</i> =0.725
	Negative n(%)	45 66%	9 16.7%		23 42.6%	31 57.4%		17 31.5%	37 68.5%		15 27.8%	39 72.2%		15 27.8%	39 72.2%	
Anti-ullRNP	Positive n(%)	27 87.1%	4 12.9%	0.003 <i>P</i> =0.956	15 48.4%	16 51.6%	0.526 <i>P</i> =0.468	8 25.8%	23 74.2%	0.251 <i>P</i> =0.616	5 16.1%	26 83.9%	2.197 <i>P</i> =0.138	10 32.3%	21 67.7%	0.279 <i>P</i> =0.597
	Negative n(%)	39 86.7%	6 13.3%		18 40%	27 60%		14 31.3%	31 68.9%		14 31.1%	31 68.9%		12 26.7%	33 73.3%	
Anti-dsDNA	Positive n(%)	36 92.3%	3 7.7%	1.227 <i>P</i> =0.268	28 71.8%	11 28.2%	26.252 <i>P</i> <0.001*	13 33.3%	26 66.7%	0.749 <i>P</i> =0.387	10 26.3%	28 73.7%	0.070 <i>P</i> =0.791	15 38.5%	24 61.5%	3.526 <i>P</i> =0.06
	Negative n(%)	30 81.1%	7 18.9%		5 13.5%	32 86.5%		9 24.3%	28 75.7%		9 23.7%	29 76.3%		7 18.9%	30 81.1%	
Anti-ribosomal P protein	Positive n(%)	35 79.5%	9 20.5%	3.471 <i>P</i> =0.062	17 38.6%	27 61.4%	0.974 <i>P</i> =0.324	18 40.9%	26 59.1%	7.27 <i>P</i> =0.007*	10 22.7%	34 77.3%	0.288 <i>P</i> =0.592	11 25%	33 75%	0.792 <i>P</i> =0.374
	Negative n(%)	31 96.9%	1 3.1%		16 50%	16 50%		4 12.5%	28 87.5%		9 28.1%	23 71.9%		11 34.4%	21 65.6%	
Anti-histone	Positive n(%)	32 82.1%	7 17.0%	0.863 <i>P</i> =0.353	30 76.9%	9 23.1%	36.599 <i>P</i> <0.001*	12 30.8%	27 69.2%	0.129 <i>P</i> =0.719	7 17.9%	32 82.1%	2.124 <i>P</i> =0.145	12 30.8%	27 69.2%	0.129 <i>P</i> =0.719
	Negative n(%)															

	Negative n(%)	34 91.9%	3 8.1%		3 8.1%	34 91.9%		10 27%	27 73%		12 32.4%	25 67.6%		10 27%	27 73%	
Anti-nucleosome	Positive n(%)	34 81%	8 19%	1.814 $P=0.178$	30 71.4%	12 28.6%	29.976 $P=0.001$ *	12 28.6%	30 71.4%	0.006 $P=0.936$	8 19%	34 81%	1.774 $P=0.183$	16 38.1%	26 61.9%	3.820 $P=0.051$
	Negative n(%)	32 94.1%	2 5.9%		3 8.8%	31 91.2%		10 29.4%	24 70.6%		11 32.4%	23 67.6%		6 17.6%	28 82.4%	

LN: Lupus Nephritis, NPSLE: Neuropsychiatric Systemic Lupus Erythematosus, * $P < 0.05$

Supplementary table 2. Anti-nuclear antibody fine specificities over time among the 72 JSLE patients

	Ever positive, n(%)	Consistently positive, n(%)	Negative seroconversion, n(%)	Positive seroconversion, n(%)	Consistently negative, n(%)
Anti- Ro52/SSA	31 43.1%	20 64.5%	5 16.1%	6 19.4%	41 56.9%
Anti- Ro60/SSA	36 50.0%	24 67%	6 16.3%	6 16.3%	36 50.0%
Anti- La/SSB	11 15.3%	5 47%	4 34.2%	2 18.5%	61 84.7%
Anti-Sm	22 30.6%	13 60%	6 26.67%	3 13.3%	50 69.4%
Anti- u1RNP	31 43.1%	16 51.7%	9 29.4%	6 18.8%	41 56.9%
Anti-dsDNA	39 54.2%	13 33%	20 51.3%	6 15.4%	33 45.8%
Anti-ribosomal P protein	44 61.1%	17 39%	23 52.3%	4 9.1%	28 38.9%
Anti-histone	39 54.2%	15 38%	16 41.4%	8 20.9%	33 45.8%
Anti- nucleosome	42 58.3%	12 28.6%	24 57.1%	7 16.7%	30 41.6%

Supplementary table 3a. Time to negative seroconversion among patients initially positive

	Time to Negative Seroconversion (months)			
	Mean±SD	Median	Minimum	Maximum
Anti-dsDNA	16.65±15.53	11.0	1.00	60.00
Anti- u1RNP	28.58±22.35	36.0	2.00	60.00
Anti-Sm	24.44±20.19	24.0	2.00	60.00
Anti- Ro52/SSA	22.20±25.15	9.0	3.00	60.00
Anti- Ro60/SSA	28.58±22.35	20.5	6.00	60.00
Anti- La/SSB	12.25±13.32	7.0	3.00	32.00
Anti- nucleosome	16.73±15.97	9.0	2.00	60.00
Anti-histone	22.29±20.39	17.5	2.00	54.00
Anti-ribosomal P protein	23.91±16.64	21	3.00	60.00

Supplementary table 3b. Time to positive seroconversion among patients initially negative

	Time to Positive Seroconversion (months)			
	Mean±SD	Median	Minimum	Maximum
Anti-dsDNA	28.00±16.63	29.0	3.0	48.0
Anti- u1RNP	27.78±20.95	23.0	1.00	60.00
Anti-Sm	39.17±22.40	45.5	6.00	60.00
Anti- Ro52/SSA	34.17±21.29	40.5	1.00	60.00
Anti- Ro60/SSA	34.33±17.83	36.0	11.00	60.00
Anti- La/SSB	60.00 ±0.00	60.00	60.00	60.00
Anti- nucleosome	33.29±20.42	29.0	10.00	60.00
Anti-histone	35.13±23.05	36.0	3.00	60.00
Anti-ribosomal P protein	47.60±12.03	46.0	36.00	60.00